Esperion to Report Third Quarter 2021 Financial Results November 2, 2021
October 12, 2021 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2021 financial results before the open of the U.S. financial markets on...
ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
September 07, 2021 16:01 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the lipid management company, today announced that it will host an investor webinar on the current landscape and future...
ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
May 04, 2021 16:01 ET
|
Esperion Therapeutics, Inc.
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL® (bempedoic acid) Tablets and...
Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal
April 27, 2021 08:00 ET
|
Esperion Therapeutics, Inc.
– First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy –– Nearly half of trial participants are women, a...
Esperion to Report First Quarter 2021 Financial Results May 4, 2021
April 12, 2021 16:01 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2021 financial results after the close of the U.S. financial markets on...
Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
February 23, 2021 16:01 ET
|
Esperion Therapeutics, Inc.
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third QuarterOver 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic...
Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021
February 09, 2021 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. financial...
Esperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 21, 2020 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39th Annual J.P....
First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland
December 16, 2020 03:00 ET
|
Esperion Therapeutics, Inc.
- NILEMDO® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and...